Combination of the anti-CD30-auristatin-E antibody-drug conjugate SGN-35 with chemotherapy improves antitumor activity in Hodgkin's lymphoma

被引：0
|
作者：
Oflazoglu, E. [1 ]
Kennedy, D. [2 ]
Sievers, E. L. [2 ]
Kissler, K. M. [1 ]
Jonas, M. [3 ]
Ihle, N. C. [4 ]
Grewal, I. S. [1 ]
Gerber, H. [1 ]
机构：
[1] Seattle Genet Inc, Preclin Therapeut, Bothell, WA USA
[2] Seattle Genet Inc, Clin, Bothell, WA USA
[3] Seattle Genet Inc, Antibody Technol, Bothell, WA USA
[4] Seattle Genet Inc, Proc Chem, Bothell, WA USA
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：235 / 236
页数：2
相关论文
共 50 条
  • [31] Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma
    Polson, A. G.
    Williams, M.
    Gray, A. M.
    Fuji, R. N.
    Poon, K. A.
    McBride, J.
    Raab, H.
    Januario, T.
    Go, M.
    Lau, J.
    Yu, S-F
    Du, C.
    Fuh, F.
    Tan, C.
    Wu, Y.
    Liang, W-C
    Prabhu, S.
    Stephan, J-P
    Hongo, J-A
    Dere, R. C.
    Deng, R.
    Cullen, M.
    de Tute, R.
    Bennett, F.
    Rawstron, A.
    Jack, A.
    Ebens, A.
    LEUKEMIA, 2010, 24 (09) : 1566 - 1573
  • [32] Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma
    A G Polson
    M Williams
    A M Gray
    R N Fuji
    K A Poon
    J McBride
    H Raab
    T Januario
    M Go
    J Lau
    S-F Yu
    C Du
    F Fuh
    C Tan
    Y Wu
    W-C Liang
    S Prabhu
    J-P Stephan
    J-A Hongo
    R C Dere
    R Deng
    M Cullen
    R de Tute
    F Bennett
    A Rawstron
    A Jack
    A Ebens
    Leukemia, 2010, 24 : 1566 - 1573
  • [33] Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives
    Prince, H. Miles
    Hutchings, Martin
    Domingo-Domenech, Eva
    Eichenauer, Dennis A.
    Advani, Ranjana
    ANNALS OF HEMATOLOGY, 2023, 102 (01) : 13 - 29
  • [34] SGN-CD30C, a new CD30-directed camptothecin antibody-drug conjugate (ADC), shows strong anti-tumor activity and superior tolerability in preclinical studies
    Ryan, Maureen
    Lyski, Ryan
    Bou, Lauren
    Meyer, David
    Jin, Steven
    Simmons, Jessica
    Benjamin, Dennis
    Senter, Peter
    Jeffrey, Scott
    CANCER RESEARCH, 2020, 80 (16)
  • [35] TARGETING CD70 IN NON-HODGKIN LYMPHOMA AND RENAL CELL CARCINOMA: A PHASE 1 STUDY OF THE ANTIBODY-DRUG CONJUGATE SGN-75
    Ansell, S. M.
    Thompson, J. A.
    Infante, J.
    Heath, E. I.
    Whiting, N. C.
    Zhao, B.
    Forero-Torres, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 174 - 174
  • [36] Phase I study of brentuximab vedotin (SGN-35) in Japanese children with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma
    Koga, Y.
    Sekimizu, M.
    Iguchi, A.
    Kada, A.
    Saito, A.
    Asada, R.
    Mori, T.
    Horibe, K.
    KLINISCHE PADIATRIE, 2020, 232 (02): : 92 - 92
  • [37] Phase I study of brentuximab vedotin (SGN-35) in Japanese children with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma
    Koga, Yuhki
    Sekimizu, Masahiro
    Iguchi, Akihiro
    Kada, Akiko
    Saito, Akiko M.
    Asada, Ryuta
    Mori, Tetsuya
    Horibe, Keizo
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (05) : 711 - 718
  • [38] Phase I study of brentuximab vedotin (SGN-35) in Japanese children with relapsed or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma
    Yuhki Koga
    Masahiro Sekimizu
    Akihiro Iguchi
    Akiko Kada
    Akiko M. Saito
    Ryuta Asada
    Tetsuya Mori
    Keizo Horibe
    International Journal of Hematology, 2020, 111 : 711 - 718
  • [39] The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease
    Wahl, AF
    Klussman, K
    Thompson, JD
    Chen, JH
    Francisco, LV
    Risdon, G
    Chace, DF
    Siegall, CB
    Francisco, JA
    CANCER RESEARCH, 2002, 62 (13) : 3736 - 3742
  • [40] Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma
    Moskowitz, Craig H.
    Forero-Torres, Andres
    Shah, Bijal D.
    Advani, Ranjana
    Hamlin, Paul
    Kim, Stella
    Kostic, Ana
    Sandalic, Larissa
    Zhao, Baiteng
    Fanale, Michelle A.
    BLOOD, 2014, 124 (21)
12345